Skip to main content
Fig. 6 | Molecular Cancer

Fig. 6

From: Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer

Fig. 6

Ascore's Prognostic and Predictive Role in Immunotherapy and Chemotherapy Cohorts. A Survival outcomes within post-immunotherapy bladder cancer patients relative to different Ascore groups. B ROC analysis of Ascore's predictive performance for survival against other prognostic factors like ECOG and liver metastasis in bladder cancer. C Response rates to immunotherapy in bladder cancer patients based on Ascore groups. D ROC analysis illustrating Ascore’s predictive accuracy for immunotherapy response in bladder cancer. E Ascore’s prognostic significance in chemotherapy-treated MIBC patients. F Assessment of Ascore in predicting pathological response to chemotherapy. (ECOG: Eastern Cooperative Oncology Group; ICIs: Immune Checkpoint Inhibitors; PD: progressive disease; SD: stable disease; PR: partial response; CR: complete response; TMB: Tumor Mutational Burden; IC: Immune Cell)

Back to article page

Molecular Cancer

ISSN: 1476-4598